There is no doubt that extended pelvic lymph-node dissection (PLND) at the time of radical prostatectomy improves the accuracy of prostate cancer staging, and there is strong evidence to indicate a ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

This Practice Point commentary discusses the paper by Dhar and colleagues, which compared outcomes between two cohorts of patients with muscle-invasive bladder cancer who received either 'limited' ...

Expert Rev Anticancer Ther. 2013;13(11):1281-1295. The extended template comprises the standard package with the addition of presacral area, the proximal common iliac and aortic bifurcation. The ...

Effect of neoadjuvant systemic therapy prior to radical prostatectomy in high-risk prostate cancer on surgical morbidity: Contemporary results utilizing the Clavien System. This is an ASCO Meeting ...

Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC) No significant financial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Compared with white men, black men with ...

Extended pelvic lymph node dissection (ePLND) is advised to complement radical prostatectomy (RP) in intermediate and high risk prostate cancer patients. To assess the risk of nodal involvement in ...

Black Men with Low-Risk Prostate Cancer Produce Less PSA After 2 years, continence, potency, and freedom from recurrence were achieved in almost half of men who had extended pelvic lymph node ...

The important part of radical prostatectomy (RP) for high risk (HR) is extended pelvic lymph node dissection (ePLND). This method consists of two stages of surgery usually performed at the compartment ...

Using real-world data, a team of U.S.-based investigators analyzed survival outcomes among an independent cohort of patients with metastatic urothelial cancer (UC) treated with immune checkpoint ...